The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

Researchers at Mayo Clinic are exploring the use of a new drug called ataciguat to manage AVS. Results from preclinical and clinical studies, published in Circulation, show that ataciguat has the ...